Spotlight on Veeva: 10 Questions with Kimberly Paris, Global Vice President of Quality Assurance
We are dedicated to accelerating the development of new drugs for patients around the world. We provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Our latest updates
News
Quotient and ANA Therapeutics announce partnership to develop drug candidate, ANA001 (niclosamide capsules) as a potential treatment for COVID-19.
Exhibition
Schedule a partnering meeting at Biotech Showcase with our CSO, Peter Scholes and Senior Director of Business Development, Katie Stuart to share your drug development needs.
Webinar
This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.
Scientific Posters
Guidance issued by the European Medicines Agency (EMA) states that patient acceptability must be an integral part of paediatric formulation development and described in the paediatric investigation plan (PIP). However, the methodology used to assess acceptability and the timing of this assessment is unclear. Previous reviews have used literature sources to review methods to assess acceptability with diverse methods reported
Ask us a question
